logo
Plus   Neg
Share
Email

Eli Lilly Announces Several Leadership Changes - Quick Facts

Eli Lilly and Co. (LLY) announced Wednesday several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations.

The company said Darren Carroll, senior vice president of corporate business development, will retire at the end of August after 22 years of service with the company.

Carroll will be succeeded by Heather Wasserman with responsibility for business development transactions, emerging technologies and innovation, and venture capital.

Meanwhile, Phil Johnson, senior vice president and treasurer, will assume additional duties overseeing merger & acquisition activity.

Levi Garraway has resigned from his position as senior vice president of oncology research and early phase development in order to pursue other opportunities. Garraway will be succeeded by Josh Bilenker, CEO of Loxo Oncology, on an interim basis.

Additionally, Frank Cunningham has been promoted to senior vice president of managed healthcare services.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT